Clinical Trial of Keytruda and Lynparza Combination Fails to Meet Primary Endpoint for Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer
“Merck revealed that its Phase III KEYLYNK-006 clinical trial, which tested a combination of Keytruda and Lynparza for the treatment of a subset of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), failed to meet the primary endpoint of improving overall survival (OS) and progression-free survival (PFS).”

Banner Health’s Ion procedure as high as 95% accurate at detecting lung cancer nodules
“Banner Health’s North Colorado Medical Center in Greeley offers robotic-assisted technology to help detect biopsy lung lesions early on among at-risk patients. John Cowden, an expert in pulmonary medicine at Banner Health, directs a technologically advanced diagnostic tool for lung cancer in northern Colorado — a robotic-assisted bronchoscopy called the Ion procedure.”

Incurable but not hopeless: How hope shapes patients’ awareness of their advanced cancer prognosis
“Hope is defined as the expectation of achieving a future good. Patients with cancer, whether it is curable or not, prioritize cure as their highest hope. Patients with incurable cancer wish to be informed about their disease and its treatment, but also need to maintain hope. This inner conflict can impact how they process information about their prognosis.”

Milken researchers find widened racial disparities in pollution-related illnesses
“Researchers examined air pollution and its associated health impacts like asthma and lung cancer from 2010 to 2019 and found that disparities in air pollution-related health complications have increased in that period. Gaige Kerr, the lead author of the study, said pollution-reducing legislation like the Clean Air Act has benefitted white communities more than communities of color because the regulations don’t resolve the history of government officials disproportionately placing pollutive factories and highways in minority neighborhoods, causing the disparity between the groups to increase.”

Oxford University developing new lung cancer vaccine
“Researchers at the University of Oxford have received a grant of £1.7 million to develop a vaccine for lung cancer.”

Racial/Ethnic Differences in Care Intensity at the End of Life for Patients With Lung Cancer
“The authors concluded: “Compared with [non-Hispanic White] patients, [Asian/Pacific Islander], Black, and Hispanic patients who died with lung cancer experienced higher intensity of [end-of-life] care. Future studies should develop approaches to eliminate such racial and ethnic disparities in care delivery at the [end of life].””

Low Screening Rates for Lung Cancer Highlight Public Health Priority
“Eligibility criteria for annual lung cancer screening (LCS) among current or former smokers should be updated, with the move going a long way to reduce screening disparities, experts emphasize today in JAMA Network Open. Their comparison of outcomes following the release of screening guidance from the US Preventive Services Task Force (USPSTF) in 2013 and updated in 2021 shows overall poor uptake of annual low-dose CT LCS, despite changes to 2 major criteria that expanded the eligibility pool: Age was lowered to 50 years from 55 to 80 years, and pack-year (PY) smoking history was reduced from 30 to 20.”

Tagrisso with the addition of chemotherapy showed favourable trend in overall survival in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 Phase III trial
“Results from the FLAURA2 Phase III trial showed AstraZeneca’s ​Tagrisso (osimertinib) with the addition of chemotherapy​ provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Tagrisso with the addition of chemotherapy also demonstrated a favourable trend toward overall survival (OS) improvement at two years of follow up. These results were presented today at the 2024 European Lung Cancer Congress (ELCC) in Prague, Czech Republic (abstract #4O).”

ChromaCode Partners With Medical College of Georgia on Non-Small Cell Lung Cancer Rapid PCR Testing
“The test utilizes ChromaCode’s high-definition PCR (HDPCR) technology, which involves machine learning algorithms and novel chemistries that increase the multiplexing capabilities of standard lab instruments. The panel covers all variants identified by the National Comprehensive Cancer Network as clinically relevant in NSCLC with a four-hour workflow for rapid results.”

Does Vaping Cause Lung Cancer?
“Vaping exposes you to thousands of chemicals, including many that cause cancer and lung disease.”


Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
“In a conversation with CancerNetwork®, Gregory Peter Kalemkerian, MD, spoke about the publication of updated guidelines for managing small cell lung cancer (SCLC) with systemic therapy, which was developed by the American Society of Clinical Oncology (ASCO) in collaboration with Ontario Health (Cancer Care Ontario).”